Söndag 12 Juli | 22:50:28 Europe / Stockholm
Est. tid*
2027-02-16 08:30 Bokslutskommuniké 2026
2026-11-03 08:30 Kvartalsrapport 2026-Q3
2026-09-01 08:30 Kvartalsrapport 2026-Q2
2026-05-29 - X-dag ordinarie utdelning IZAFE B 0.00 SEK
2026-05-28 - Årsstämma
2026-04-28 - Kvartalsrapport 2026-Q1
2026-03-12 - Extra Bolagsstämma 2026
2026-02-16 - Bokslutskommuniké 2025
2025-11-03 - Kvartalsrapport 2025-Q3
2025-08-29 - Kvartalsrapport 2025-Q2
2025-05-30 - X-dag ordinarie utdelning IZAFE B 0.00 SEK
2025-05-28 - Årsstämma
2025-04-25 - Kvartalsrapport 2025-Q1
2025-02-14 - Bokslutskommuniké 2024
2024-11-01 - Kvartalsrapport 2024-Q3
2024-08-30 - Kvartalsrapport 2024-Q2
2024-05-31 - X-dag ordinarie utdelning IZAFE B 0.00 SEK
2024-05-30 - Årsstämma
2024-04-26 - Kvartalsrapport 2024-Q1
2024-02-09 - Bokslutskommuniké 2023
2023-12-21 - Extra Bolagsstämma 2024
2023-11-17 - Kvartalsrapport 2023-Q3
2023-08-25 - Kvartalsrapport 2023-Q2
2023-05-12 - Kvartalsrapport 2023-Q1
2023-04-06 - X-dag ordinarie utdelning IZAFE B 0.00 SEK
2023-04-05 - Årsstämma
2023-02-03 - Bokslutskommuniké 2022
2022-11-07 - Kvartalsrapport 2022-Q3
2022-10-05 - Extra Bolagsstämma 2022
2022-08-26 - Kvartalsrapport 2022-Q2
2022-06-15 - X-dag ordinarie utdelning IZAFE B 0.00 SEK
2022-06-14 - Årsstämma
2022-04-29 - Kvartalsrapport 2022-Q1
2022-02-18 - Bokslutskommuniké 2021
2021-11-29 - Kvartalsrapport 2021-Q3
2021-09-23 - Extra Bolagsstämma 2021
2021-08-30 - Kvartalsrapport 2021-Q2
2021-06-28 - Årsstämma
2021-06-15 - X-dag ordinarie utdelning IZAFE B 0.00 SEK
2021-04-29 - Kvartalsrapport 2021-Q1
2021-02-19 - Bokslutskommuniké 2020
2020-11-09 - Kvartalsrapport 2020-Q3
2020-08-17 - Kvartalsrapport 2020-Q2
2020-06-26 - X-dag ordinarie utdelning IZAFE B 0.00 SEK
2020-06-25 - Årsstämma
2020-05-11 - Kvartalsrapport 2020-Q1
2020-02-20 - Bokslutskommuniké 2019
2019-05-10 - X-dag ordinarie utdelning IZAFE B 0.00 SEK
2019-05-06 - Kvartalsrapport 2019-Q1
2019-04-10 - Årsstämma
2019-02-28 - Bokslutskommuniké 2018
2018-12-18 - Extra Bolagsstämma 2018
2018-10-24 - Kvartalsrapport 2018-Q3
2018-08-29 - Kvartalsrapport 2018-Q2
2018-05-24 - Kvartalsrapport 2018-Q1
2018-04-12 - X-dag ordinarie utdelning IZAFE B 0.00 SEK
2018-04-11 - Årsstämma
2018-03-22 - Bokslutskommuniké 2017
2017-08-29 - Kvartalsrapport 2017-Q2
2017-05-09 - Kvartalsrapport 2017-Q1
2017-04-26 - X-dag ordinarie utdelning IZAFE B 0.00 SEK
2017-04-25 - Årsstämma
2017-02-24 - Bokslutskommuniké 2016
2016-11-16 - Kvartalsrapport 2016-Q3
2016-10-19 - Extra Bolagsstämma 2016
2016-08-31 - Kvartalsrapport 2016-Q2
2016-04-20 - Kvartalsrapport 2016-Q1
2016-02-25 - X-dag ordinarie utdelning IZAFE B 0.00 SEK
2016-02-24 - Årsstämma
2016-02-04 - Bokslutskommuniké 2015
2015-11-13 - Kvartalsrapport 2015-Q3
2015-09-04 - Kvartalsrapport 2015-Q2
2015-07-22 - Extra Bolagsstämma 2015
2015-05-07 - X-dag ordinarie utdelning IZAFE B 0.00 SEK
2015-05-06 - Årsstämma
2015-04-17 - Kvartalsrapport 2015-Q1
2015-02-20 - Bokslutskommuniké 2014
2014-12-17 - Extra Bolagsstämma 2014
2014-11-28 - Kvartalsrapport 2014-Q3
2014-11-14 - Kvartalsrapport 2014-Q3
2014-08-29 - Kvartalsrapport 2014-Q2
2014-06-12 - X-dag ordinarie utdelning IZAFE B 0.00 SEK
2014-06-11 - Årsstämma
2014-05-16 - Kvartalsrapport 2014-Q1
2014-02-21 - Bokslutskommuniké 2013
2013-11-15 - Kvartalsrapport 2013-Q3
2013-08-28 - Kvartalsrapport 2013-Q2
2013-06-17 - X-dag ordinarie utdelning IZAFE B 0.00 SEK
2013-06-14 - Årsstämma
2013-05-17 - Kvartalsrapport 2013-Q1
2013-02-22 - Bokslutskommuniké 2012
2012-11-30 - Kvartalsrapport 2012-Q3
2012-07-31 - Kvartalsrapport 2012-Q2
2012-06-20 - X-dag ordinarie utdelning IZAFE B 0.00 SEK
2012-06-19 - Årsstämma
2012-04-20 - Kvartalsrapport 2012-Q1
2012-02-21 - Bokslutskommuniké 2011
2011-11-04 - Kvartalsrapport 2011-Q3
2011-08-12 - Kvartalsrapport 2011-Q2
2011-05-06 - Kvartalsrapport 2011-Q1
LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
iZafe Group är ett Life Science-bolag inriktat på utveckling och marknadsföring av digitala medicinska lösningar för läkemedelshantering i hemmet. Bolaget erbjuder bland annat en läkemedelsrobot, SaaS-lösningar och en uppkopplad dosettask. Produkterna ämnar minska risken för felmedicinering. Kunderna utgörs av privatpersoner, läkemedelsbolag samt offentliga och privata vårdgivare globalt. iZafe Group har sitt huvudkontor i Stockholm.

Analysera bolaget i Börsdata!

All ägardata du vill ha finns i Holdings!

iZafe Group AB carries out the first partial payment for the acquisition of its Dutch subsidiary through a set-off issue of B shares

2026-07-10 14:00:00

In September 2025, iZafe Group AB, reg. no. 556762-3391 (“iZafe” or the “Company”), acquired the Dutch company Thuisapparatuur Nederland B.V. (“TAN”). iZafe has today entered into an addendum agreement with Stichting TCCN, the seller of TAN, under which the first partial payment for the acquisition, corresponding to a total of approximately EUR 310,000, will be paid in full through a new issue of a total of 10,386,409 B shares in iZafe at a subscription price of SEK 0.33 per B share.

The first partial payment for the acquisition relates to approximately EUR 170,000 in amortisation of loans from TAN to the seller, which were assumed by iZafe in connection with the acquisition. The remaining approximately EUR 140,000 relates to a partial payment of the purchase price for the acquisition. Following the first partial payment, EUR 1.24 million remains to be paid for the acquisition, of which approximately EUR 680,000 relates to repayment of assumed loans and approximately EUR 560,000 relates to the cash purchase price.

Payment of the remaining part of the acquisition will, as previously communicated, be made in six instalments during the period from 31 January 2027 to 31 July 2029, where the first instalment corresponds to 20 percent of the total amount and the remaining amount thereafter is distributed equally over the final five instalments.

The subscription price per B share amounts to approximately SEK 0.33, corresponding to the volume-weighted average price during the ten (10) trading days preceding the agreement date, with a discount of approximately 10.4 percent. Payment for the new B shares will be made in full by way of set-off against claims relating to the first partial payment for the acquisition of TAN.

The issue entails that the number of shares and votes in the Company increases by 10,386,409, from 430,591,337 shares, of which 600,000 are A shares, to 440,977,746 shares, of which 600,000 are A shares. The share capital increases by SEK 519,320.45, from SEK 21,529,566.85 to SEK 22,048,887.30. The issue entails a dilution effect of approximately 2.36 percent of the number of shares in the Company.

The issue will be resolved by the Board of Directors pursuant to the authorisation granted by the Annual General Meeting on 28 May 2026 and is expected to be completed no later than 31 July 2026.

Reasons for deviation from the shareholders’ preferential rights, etc.

The reason for deviating from the shareholders’ preferential rights is to carry out the first partial payment for the acquisition of TAN in a time- and cost-efficient manner without affecting the Company’s short-term liquidity position.

The Board of Directors has carefully considered alternative financing options, including carrying out a rights issue. Taking into account the limited size of the issue, the expected time required and the costs associated with alternative financing solutions, the Board of Directors has found that a directed new share issue to the seller is the most appropriate solution. The Board’s overall assessment is therefore that a directed issue is beneficial to both iZafe and its shareholders, and that the reasons for deviating from the shareholders’ preferential rights outweigh the reasons for carrying out a rights issue.

The subscription price has been agreed through arm’s length negotiations with the counterparty and is considered to be market-based, as it is based on the volume-weighted average price during the ten (10) trading days preceding the signing of the agreement, with an issue discount that is slightly lower than the issue discount applied in the Company’s most recent directed new share issue.